Japan approval, a 27% surge: the diagnostics stock our models picked in September
Natera, a diagnostics stock, has surged by 27% since the beginning of September, reaching new all-time highs. Investing.com's ProPicks AI-powered Strategies added Natera to its portfolio on September 1, capitalizing on three distinct catalysts that drove the increase. On September 18, Natera unveiled the largest-ever minimal-residual-disease study in lung cancer, showing that Signatera-negative patients had a 25-percentage-point higher three-year recurrence-free survival rate compared to positive patients.
Later on September 22, Japan's PMDA approved Signatera as a companion diagnostic for muscle-invasive bladder cancer, with a commercial launch scheduled for the first half of 2027. The stock's consensus price target stands at $330.83, with 23 analysts rating the stock as a strong buy or buy. Natera's performance has outperformed the S&P 500 Health Care index by 2.37 percentage points in September.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
